Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Niktoraal
- Development stage
- Preclinical
- Lead developer
- Kian Immune Cell Company
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Niktoraal is an NKT cell-based therapy developed by Kian Immune Cell Company for the treatment of solid tumors. Natural Killer T (NKT) cells are a specialized subset of lymphocytes that bridge the innate and adaptive immune systems. They express a semi-invariant T-cell receptor (TCR) that recognizes glycolipid antigens presented by the CD1d molecule. Niktoraal is designed to harness the potent cytotoxic capabilities of NKT cells and their ability to rapidly produce cytokines, thereby modulating the tumor microenvironment and promoting a robust anti-tumor immune response. The product is currently in preclinical development.
- Brand names
- Niktoraal
Beyond the preview
Go deeper on Niktoraal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Niktoraal.